NASDAQ:KPTI Karyopharm Therapeutics Q4 2023 Earnings Report $5.62 -0.35 (-5.86%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$5.76 +0.14 (+2.49%) As of 04/25/2025 07:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Earnings HistoryForecast Karyopharm Therapeutics EPS ResultsActual EPS-$5.40Consensus EPS -$4.35Beat/MissMissed by -$1.05One Year Ago EPS-$6.45Karyopharm Therapeutics Revenue ResultsActual Revenue$33.75 millionExpected Revenue$33.50 millionBeat/MissBeat by +$250.00 thousandYoY Revenue GrowthN/AKaryopharm Therapeutics Announcement DetailsQuarterQ4 2023Date2/29/2024TimeBefore Market OpensConference Call DateThursday, February 29, 2024Conference Call Time8:00AM ETUpcoming EarningsKaryopharm Therapeutics' Q1 2025 earnings is scheduled for Tuesday, May 6, 2025, with a conference call scheduled on Wednesday, May 7, 2025 at 8:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesConference Call AudioConference Call TranscriptSlide DeckPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfileSlide DeckFull Screen Slide DeckPowered by Karyopharm Therapeutics Q4 2023 Earnings Call TranscriptProvided by QuartrFebruary 29, 2024 ShareLink copied to clipboard.There are 9 speakers on the call. Operator00:00:00Good morning. My name is Ludi, and I will be your conference operator today. At this time, I would like to welcome everyone to the Curuform Therapeutics 4th Quarter and Full Year 2023 Financial Results Conference Call. There will be a question and answer session to follow. Please be advised that this call is being recorded at the company's request. Operator00:00:21I would now like to turn the call over to Ellen Webb, Senior Vice President of Investor Relations. Please go ahead. Speaker 100:00:28Thank you, Luthie, and thank you all for joining us on today's conference call to discuss our financial results and recent company progress. We issued a press release this morning detailing our financial results for the Q4 and full year 2023. This release along with a slide presentation that we will reference during our call today are available on our website. For today's call, as seen on Slide 2, I'm joined by Richard, Reshma, Soania and Mike, who will provide an update on our results for the Q4 and full year 2023 and recent clinical developments. Before we begin our formal comments, I'll remind you that various remarks we'll make today constitute forward looking statements as follows for purposes of the Safe Harbor provisions under the Private Securities Litigation Reform Act of 1995 as outlined on Slide 3. Speaker 100:01:24Actual results may differ materially from those indicated by these FLX as a result of various important factors, including those discussed in the Risk Factors section of our most recent Form 10Q or 10 ks, which are on file with the SEC and in other filings that we may make with the SEC in the future. Any FLS represents our views as of today only. While we may elect to update these FLS at some point in the future, we specifically disclaim any obligation to do so even if our views change. Therefore, you should now rely on these FLS as Speaker 200:02:12Good morning. Thank you, Alhan, and thank you for joining us today for Karyopharm's Q4 and full year 2023 earnings call. My name is Richard Paulson, President and Chief Executive Officer of Karyopharm. As you can see on Slide 5, over the past few years, we have been intensely focused on positioning ourselves for our next stage of growth with 3 late stage trials supported by a growing body of unprecedented data in both solid and hematological malignancies that are expected to read out next year. The data we are seeing in myelofibrosis and endometrial cancer are highly encouraging and we believe the largest opportunities for selinexor are yet to come. Speaker 200:02:59These trials will potentially enhance and create new standards of care for patients and provide significant value creation opportunities in the near term. It is our top priority to advance this late stage pipeline, address patients' unmet needs and if approved, rapidly expand selinexor's use in new indications. We are doing this by concentrating our investments into these pivotal programs and leveraging our existing multiple myeloma franchise anchored on our commercial drug, EXPOVIO, which is approved in over 40 countries, generating brand profitability and growing experience with physicians. Through ongoing disciplined expense management, we have In 2023, we delivered total revenues of $146,000,000 meeting our guidance for full year and in 2024 we expect to generate $140,000,000 to $160,000,000 total revenues. This range reflects the highly competitive nature of the multiple myeloma market with important new entrants in the second half of twenty twenty three and more anticipated this year, which we are mindful of especially when setting expectations for our financial performance this year. Speaker 200:04:25This is balanced by the resilience we have demonstrated and our focus on both near term and long term growth. Importantly, our existing commercial infrastructure is profitable today and provides us with the capability to support the rapid and smooth commercial launch of selinexor in new indications. We are committed to delivering on the opportunities ahead of us and believe selinexor could generate approximately $2,000,000,000 of peak annual revenues in the U. S. Alone. Speaker 200:04:58And turning now to Slide 6, let's review some key accomplishments from our core programs in 2023, which strengthen our confidence in our ongoing Phase 3 trials. In myofibrosis, we are very encouraged by the comprehensive profile, including tolerability, spleen volume reduction, symptom improvement as measured by TSS-fifty and the long term durability that we saw in our Phase 1 data of selinexor plus ruxolitinib in JAK naive patients presented at ASH. In endometrial cancer, we are excited by the substantial improvement in median progression free survival for patients who are TP53 wild type as reported at the ASCO plenary series. This highlights the opportunity we may have to deliver unprecedented outcomes for a large and unique population of patients. In multiple myeloma, despite increased competition in the academic setting, we continued to grow EXPOVIO in the community setting and shifted its use to earlier lines of treatment. Speaker 200:06:06We look forward to the results from our Phase 3 trial evaluating selinexor at the well dose of 40 milligrams in combination with the well established backbone therapy of pomalidomide and dexamethasone post anti CD38 antibodies. Turning now to Slide 7, as we work to create new standards of care, we expect each of our ongoing Phase 3 clinical trials will read out top line results in 2025. Any one of these programs if approved represents an incredibly meaningful growth opportunity for our company with endometrial cancer and myelofibrosis representing the largest opportunities. Moving to Slide 8, I would now like to turn the call over to Reshma to expand further on our clinical pipeline progress. Reshma? Speaker 300:06:58Thank you, Richard, and good morning, everyone. As Richard mentioned on Slide 9, we have a very promising late stage pipeline with selinexor in 3 Phase 3 studies, all of which incorporate selinexor doses at 40 or 60 milligrams once weekly. Let's now turn our attention to myelofibrosis on Slide 11. Ruxolitinib remains the standard of care for the majority of JAK naive patients. However, there is an opportunity to improve benefit given that the efficacy with ruxolitinib is limited, with only about 35% of patients achieving an SVR35 and less than half of all patients achieving meaningful symptom improvement. Speaker 300:07:41Xpl1 inhibition is a fundamental mechanism in myelofibrosis, given that it targets both JAK and non JAK pathways, underscoring selinexor's additive is not potentially synergistic activity when dosed in combination. We are evaluating the potential for selinexor in combination with ruxolitinib to provide benefit across all of the hallmarks of the disease, including spleen reduction, symptom improvement, disease modification and stabilization, if not improvement of the cytopenias. As you can see on Slide 12, we presented updated data last year from our trial evaluating selinexor 60 milligrams with ruxolitinib in JAK inhibitor naive patients, which showed an SVR35 of 79% at week 24 in the intent to treat population. Importantly, amongst the evaluable patients, 100% achieved in SVR35 at any time. On Slide 13, both TSS 50 and absolute TSS showed very meaningful improvements at week 24. Speaker 300:08:4858% of the intent to treat and 78% of the efficacy evaluable achieved the TSS 50 response. For absolute TSS, an average 18.5 point improvement was observed in the efficacy evaluable population at the same time point. Compare these to historical ruxolitinib data where TSS 50 was observed in 42% to 46% of ruxolitinib treated patients and the average TSS improvement was 11 to 14 points. Moreover, on Slide 14, we see that all symptom domains are substantially improved with the selinexor combination with all domains achieving an approximately 50% or greater improvement compared to baseline. The absolute TSS, TSS-fifty and individual domain improvements are corroborated by cytokine data, which show that the pro inflammatory cytokines, which lead to myelofibrosis symptom development show rapid, deep and sustained reductions relative to baseline. Speaker 300:09:54Taken together, data demonstrate that the novel combination of selinexor plus ruxolitinib has the potential to maximize symptom improvement relative to ruxolitinib alone in the ongoing Phase 3 study. Shown on Slide 15, we find the durability data from the selinexor ruxolitinib combination very important for patients. As of the most recent data cut off, none of the week 24 SVR35 responders dosed at selinexor 60 milligrams had observed radiographic progressions and none of the week 24 TSS 50 responders had observed symptom progressions. While I acknowledge the apparent limitations in cross trial comparisons, contrast these data to ruxolitinib alone in which only approximately 70% of responses were ongoing at 78 weeks. As we move to Slide 16, when we look at SVR35 and TSS 50 together, we see that 50% of patients experienced both of these responses at week 24 and 75% experienced both SBR35 and TSS50 response at any time. Speaker 300:11:06On Slide 17, we see that in addition to the cytokine data, we also observed signs of disease modification with the stabilization in the hemoglobin levels of patients on Selinexor 60 milligrams in combination with ruxolitinib. This trend is unique with the Selinexor combination given that with ruxolitinib alone, hemoglobin levels drop after treatment initiation and tend to stay low. On Slide 18, prominent myelofibrosis leaders in the field are impressed with the profile this unique selinexor combination may provide JAK naive myelofibrosis patients. In fact, one of the most prominent opinion leaders and the principal investigator of the selinexor plus ruxolitinib Phase 3 study, Doctor. John Mascarenas noted that the combination is tolerable and that the spleen and symptom data observed to date from the Phase 1 study may significantly improve these outcomes in first line myelofibrosis. Speaker 300:12:05As the body of data grow and positively evolve, we maintain a high level of confidence in the ongoing Phase 3 study shown on Slide 19, which is evaluating the combination of selinexor 60 milligrams with ruxolitinib versus ruxolitinib alone in 306 JAK naive myelofibrosis patients. We are on track to report top line results in the second half of twenty twenty five. Turning now to endometrial cancer. As seen on Slide 21, there is a paradigm shift underway for treatment of women with advanced and recurrent endometrial cancer, the most common form of gynecologic cancer in the United States with increasing use of molecular classification. TP53 wild type represents a potentially unique, but fundamental biomarker in endometrial cancer. Speaker 300:12:58Today, for DMMR patients who represent approximately 20% of advanced recurrent endometrial cancer, the new FDA approved standard is dastarlimab in combination with chemotherapy, followed by dastarlimab maintenance. For PMMR, which represent the remaining 80% of patients, checkpoint inhibitors are not approved. As such, the primary treatment option is chemotherapy followed by watch and wait. Patients whose tumors are both PMMR and p53 wild type represent 40% to 55% of all advanced recurrent endometrial cancer patients. As you can see on Slide 22, long term follow-up from the TP53 wild type subgroup from the SIENDRA trial, which evaluated selinexor as a maintenance therapy and thus after completion of approximately 6 months of chemotherapy shows a median PFS for selinexor of 27.4 months and 5.2 months for placebo, corresponding to a hazard ratio of 0.41. Speaker 300:14:04These robust subgroup data demonstrate the potential to provide substantial benefit to a unique and sizable population defined by p53 status, which directly ties to selinexor's mechanism of action given that XPO1 inhibition retains p53 within the nucleus, thus enhancing cell kill. As shown on Slide 23, the benefit observed with selinexor in the PMMR subpopulation is even more impressive with a hazard ratio of 0.32 and a median PFS that was not reached as of our most recent data cut off. The preliminary overall survival is encouraging with the hazard ratio of 0.76 observed in all patients with TP53 wild type and hazard ratio of 0.57 in the subgroup of patients that are p53 wild type and PMMR. These efficacy data coupled with the generally manageable side effect profile suggests that oral selinexor is uniquely positioned as an optimal maintenance therapy where convenience, tolerability and meaningful efficacy are the hallmarks of the maintenance option. In fact, some of our patients are now reaching their 4th year on therapy. Speaker 300:15:21I'm excited to present additional follow-up data later this year. On Slide 24, you can see the design of our EC-forty two pivotal Phase 3 study, which will enroll approximately 220 women whose tumors are PP53 wild type. We look forward to presenting top line results in the first half of 2025. Turning now to multiple myeloma. As seen on Slide 26, we are expanding our multiple myeloma franchise with the ongoing Phase 3 trial that is evaluating selinexor at the low dose of 40 milligrams in combination with the well established backbone therapy of pomalidomide and dexamethasone post anti CD38 antibodies, which will drive earlier use. Speaker 300:16:07We are enrolling patients with relapsed refractory multiple myeloma who have received an anti CD38 antibody as their most recent therapy. As we are seeing positively evolving data with longer median CSS observed with selinexor 40 milligrams in combination with pomalidomide and dexamethasone, a beneficial outcome for these patients. Top line data are now expected in the first half of twenty twenty five. In summary, we have near term late stage opportunities supported by compelling data in our rapidly advancing pipeline that will potentially benefit multiple cancer patient populations of high unmet need building on our approved indications. With that, I will now hand it over to Solania to review our commercial highlights. Speaker 300:16:55Turning now to Slide 28 and our commercial highlights for the Q4 and full year 2023. In 2023, we achieved $112,000,000 Exovio net revenue meeting our guidance for the year. In the Q4 2023, exovio net revenues were 25,000,000 dollars During 2023, we achieved total demand growth in the community setting and shifted patient mix into earlier lines consistent with our strategy. We increased our breadth of use, growing our community prescribing sites of care by approximately 20% year over year. The community setting now represents 2 thirds of our business and is where the large majority of early aligned patients are treated. Speaker 300:17:46In Q4 2023, EXPOVIO new patient share was approaching 70% in the second to fourth lines, representing double digit growth year over year. This shift in mix of patients continues to drive higher refills as earlier line patients tend to stay on therapy longer. We faced some considerable headwinds in 2023, including increased competition from new entrants in the bispecific class in the later lines, which adversely impacted demand in the academic setting in the second half of twenty 23. Additionally, higher gross to net driven by increased 340B discounts and Medicaid rebates due to the Inflation Reduction Act and a significant increase in the free drug or patient assistance program utilization due to closures of multiple myeloma foundations adversely impacted our revenue. In 2023, PAP contributed to 10% of total demand versus 5% in 2022, resulting in roughly a $6,000,000 impact in 2023. Speaker 300:18:57As we turn to 2024, we are working to grow our multiple myeloma business versus last year and are guiding to a U. S. Exovio net product revenue range of $100,000,000 to 120,000,000 dollars We believe our guidance range reflects a balance of conviction in our near term growth strategy for XBOVIO, while also recognizing the increasingly competitive nature of the myeloma landscape. For Xpovio, we remain focused on growth in 3 key areas. 1st, the community setting. Speaker 300:19:34This is where majority of physicians tend to treat early aligned patients and are looking for agents that are effective, manageable and convenient. We believe that as DARZALEX use expands in the frontline, particularly in the community setting, it opens up new opportunities for XPOVIO in the 2nd or 4th lines. This is strengthened by our new data and elevation of selinexor in the NCCN guidelines. 2nd, earlier lines of therapy. We will remain focused on further shifting the use of selinexor into earlier lines of therapy where we see the benefit of increasing duration of therapy. Speaker 300:20:163rd, T cell fitness. We plan to further build on the evidence around the effectiveness of exposure pre and post T cell redirecting therapies, enabling a flexible position for selinexor in the treatment paradigm as a novel mechanism of action. As we look to the future of our multiple myeloma franchise, we believe that as a profitable business, generating a 2:one ROI, it will continue to provide a steady inflow of cash to fuel our pipeline and continue to drive confidence and experience in our product at a lower dose as we prepare for future launches, including the potential approval of the all oral SPD regimen, which could unlock further growth. Our story in multiple myeloma has been one of resilience and steadfastness in a highly competitive and rapidly evolving environment, where the disease remains incurable and EXPOVIO continues to be an effective option for many patients. Finally, our commercial organization is well established and has developed deep relationships in the community, which represents a key overlapping customer base in both myelofibrosis and endometrial cancer to enable rapid launches in these areas. Speaker 300:21:42Now I would like to turn the call over to Mike to give an update on our financials. Speaker 200:21:48Good morning, everyone, and thank you, Suhania. Turning to our financials, since we issued a press release earlier today with the full financial results, I will just focus on the highlights, which begin on Slide 30. Total revenue for the Q4 of 2023 was $33,700,000 similar to total revenue in the Q4 of 2022. Total revenue for the full year 2023 was $146,000,000 compared to $157,100,000 for the full year 2022. Net product revenue from U. Speaker 200:22:18S. Commercial sales of XPOVIO for the Q4 of 2023 was $25,100,000 compared to $31,100,000 for the Q4 of 2022. Net product revenue from U. S. Commercial sales of XPOVIO for the full year 2022 was $112,000,000 compared to $120,400,000 for the full year of 2022. Speaker 200:22:40The gross to net discount for XPOVIO in the Q4 of 2023 was 23.5% and for the full year 2023 was 22%. We expect the gross to net discount to be in the 25% to 30% range for the full year 2024 and as seen in previous years, it is expected to be at the higher end of the range for Q1. R and D expenses for the Q4 of 2023 were $39,400,000 compared to $30,900,000 for the Q4 of 2022 and $138,800,000 for the full year of 2023 compared to $148,700,000 for the full year 2022. The decrease in R and D expenses was primarily attributable to the decrease in personnel costs as a result of the reduction in headcount in line with the prioritization of our late stage clinical pipeline and decrease in severance related expenses. These decreases were partially offset by an increase in clinical trial and related costs, primarily due to the advancement of our 3 pivotal Phase III studies, which is expected to slightly increase our R and D expenses in 2024. Speaker 200:23:52SG and A expenses for the Q4 of 2023 were $30,700,000 compared to $34,600,000 for the Q4 of 2022. SG and A expenses for the full year of 2023 were $131,900,000 compared to $145,400,000 for the full year 2022. The decrease in SG and A expenses in 2023 compared to 2022 were due to a decrease in stock based compensation because of severance related expenses incurred in 2022. In 2024, we expect our SG and A expenses to slightly decrease as we continue to seek the benefits of our cost optimization efforts. On a non GAAP basis, which excludes stock based compensation, our total R and D and SG and A expenses in 2023 were $249,300,000 in line with our guidance for the year. Speaker 200:24:44Cash, cash equivalents, restricted cash and investments as of December 31, 20 Based on our current operating plans, we are expecting total revenue of $140,000,000 to $160,000,000 for 20.24 consisting of U. S. Exfoliovio net product revenue and license, royalty and milestone revenue expected to be earned from our partners, primarily Menarini and Antigene. We expect U. S. Speaker 200:25:17Exfoliovo net product revenue of $100,000,000 to $120,000,000 R and D and SG and A expenses to be in the range of $260,000,000 to $280,000,000 for the full year of 2024, including expected stock based compensation expense of 20 $1,000,000 to $25,000,000 And finally, that our existing cash, cash equivalents and investments as well as the revenue we expect to generate from XPOVIO net product sales and other license revenues will be sufficient to fund our planned operations into late 2025. In summary, we continue to be very diligent in allocation of our resources and looking at our projected 2024 expenses, we see the results of our pipeline prioritization and headcount reductions over the past couple of years. We are rapidly advancing our 3 Phase III trials and driving our commercial performance while keeping overall expense growth minimal. I'll now flip to Slide 31 and turn the call over to Richard for some final thoughts. Richard? Speaker 200:26:15Thank you, Mike. As you can see on Slide 32, we are excited about our innovation and growth strategy with our Phase 3 clinical trials in multiple myeloma, endometrial cancer and myelofibrosis, each of which would be transformative for patients and our organization. As I mentioned at the start of the call, we believe the largest opportunities for selinexor are yet to come. With data expected from these 3 Phase 3 trials next year, it's going to be an incredibly exciting time for our organization. We are focused on delivering on our next phase of growth as our people continue to strive each day for patients with high unmet needs, working to generate value for patients and shareholders. Speaker 200:27:01Thank you again for joining us today. And I would now like to ask the operator to open the call up to the Q and A portion of today's call. Operator? Operator00:27:12Thank you. You. And your first question comes from the line of Peter Lawson from Barclays. Your line is open. Speaker 400:27:44Great. Thanks so much. Maybe a question for Mike or Sonia, just around there's any way to kind of quantify the community versus academic setting growth in 'twenty three and kind of what that you think that looks like exiting the year and into 2024? Speaker 200:28:05Yes. Thanks, Peter, for the question. I think when you look overall, I think as Sonja talked to during our prepared comments, you really need to differentiate the environment between the community setting and the academic setting. And I'll turn to Sohane to elaborate on that looking at 2023 into 2024. Speaker 300:28:23Thanks, Peter, for the question. In 2023, as we take a step back, despite the rapid evolution in the competitive landscape, we did achieve total demand growth year over year in 20 23 in the community setting. This is an area of hyper focus for us and a clear growth driver for us in 2024. Another key accomplishment in the community for us in 2023 is we really broadened our sites of care. So we now have a broad base of prescribers. Speaker 300:28:57We increased our prescriber base by about 20% year over year. That is an area where we want to drive depth in the community in 2024. Again, this is the largest contributor of our business. It's about 2 thirds of our business. Switching to the academic setting that contributes to about a third of our business, and this is where we see rapid evolution of the competitive landscape. Speaker 300:29:22So last year, we were really in the eye of the storm, especially in the second half of the year, where we saw downward demand pressure as a result of the uptake of the bispecific class. 2 of the 3 bispecifics launched in the second half of last year. Now as we move into 2024, we do see a couple of new dynamics come into play, potential approval of a 4th bispecific potential shifts of CAR Ts into earlier lines. However, in terms of defending our business in the academic setting, it's really around enabling a flexible position for selinexor as a novel mechanism that's easily combinable and supported by our T cell fitness data. So that allows us to really play in the potential pre and post T cell therapy space in the academic setting. Speaker 400:30:19Perfect. Thank you. And then just the impact of BCMA therapies, do you think that kind of continues through 2024? Have you seen kind of the major shift already kind of happened? Speaker 300:30:34Yes. So the bispecifics, as I touched on, really posed a significant competitive threat in the academic setting, particularly in the second half of last year. As I mentioned, 2 of the 3 launched in the second half. Now we haven't seen that uptake in the community. We think that's going to be minimal impact in the near term in the community. Speaker 300:30:59But in the academic setting, we definitely saw impact. Now in real world, we are seeing that these patients are on bispecifics for about 8 to 9 months. Many are progressing. So it's not a curable option. As we think about the role of selinexor relative to the bispecifics, we have published data on positive outcomes post BCMA failures. Speaker 300:31:24So that really allows us to position ourselves after a bispecific and in many cases pre bispecifics as well. Speaker 400:31:35Thank you so much. I'll jump back into the queue. Speaker 200:31:39Thanks, Peter. Operator00:31:40Thank you. And your next question comes from the line of Maury Raycroft from Jefferies. Your line is open. Speaker 500:31:50Hi, good morning and thanks for taking my questions. I was going to ask 1 or 2 on myelofibrosis. Wondering what your thoughts are on the recent acquisition of MorphoSys and what read throughs there would be to carry a farm based on how the regulatory process could play out, particularly on the TSS endpoint, which was their key secondary, but is your co primary endpoint? And could you potentially have further conversations with FDA prior to filing and or change the study design, if need be? Speaker 200:32:23Thanks, Maury. I'll take the first part of that and then I'll turn it over to Reshma to take the second part of that. I think when you look at the Novartis and MorphoSys acquisition, it really validates the high unmet need in the myelofibrosis space and really talks to the value of the opportunity of myelofibrosis. So I think that's a strong validation of the value and the unmet need in myelofibrosis. And I'll turn to Reshma to talk about what we're looking at in terms of the evolution and I think we're really in a strong opportunity to watch the evolution of the space as it moves forward. Speaker 300:33:00Yes, exactly. And thank you for the question, Maury. I think what we presented today really just outlines the strength that we have across the entire profile of selinexor ruxolitinib, specifically the optimal spleen volume reduction, the symptom improvement, right, not only from a TSS-fifty perspective, but also now absolute TSS-fifty. We further looked at individual domains seeing maximal effect across each of the individual domains too. And all of that is of course underscored by the cytokine data. Speaker 300:33:35So really a wealth and growing sort of data set around that symptom score that really suggests that we can maximize benefit across both of those endpoints. Let's not forget disease modification and then of course improvement and stabilization of the cytopenia. So again, really just emphasizing that we have the totality profile that is going to be optimal for this JAK naive patient population. We're very encouraged and we're very confident that when we look at symptoms in our Phase 3, it is going to show meaningful benefit compared to selinexor alone. As Richard mentioned, I think we've got the best opportunity, right? Speaker 300:34:18We have an ongoing Phase 3. It's currently enrolling. We do know that the environment is evolving, both from a physician perspective, but also from an FDA perspective. And we're going to capitalize on that. So if there's an opportunity to evolve the endpoints, we have an opportunity to then of course incorporate those into our study prior to the database lock. Speaker 500:34:46Okay. That's helpful. And maybe one other question. You plan to report the preliminary results from the monotherapy Phase 2 inject naive myelofibrosis with moderate thrombocytopenia in the second half of this year. Can you talk more about what the strategy is for that study? Speaker 500:35:04Is this for potential standalone monotherapy approval path or more for supplementing the combination filing in label? Speaker 300:35:12Yes. Great question. So one of the unique aspects of selinexor is that when we look at preclinical data, obviously, clinical data from a relapsed refractory myelofibrosis study, which is the essential study. And then of course the subgroup data from our Phase 1 selinexor plus ruxolitinib, it all points to very intriguing monotherapy activity. Again, this is unique. Speaker 300:35:36When you look at other mechanisms of action, whether it's a BET inhibitor or a BCL2 inhibitor, those agents by and large do not have that critical monotherapy activity. It's key that physicians ultimately have that flexibility in that dosing. We want to use this Phase 2 study to further investigate this monotherapy activity in this high Aetna patient population. We'll have an opportunity to read out some data later this year and really be able to identify whether that activity is meaningful again in that high net need patient population. We're really looking at this as a proof of concept study. Speaker 300:36:20Potentially, we can expand it, potentially get some NCCN, but right now, it's really to double down and better test this hypothesis that we have with selinexor again in this JAK naive population. Speaker 500:36:32Got it. Okay. Thanks for taking my questions. Speaker 200:36:35Thanks, Marty. Operator00:36:38And your next question comes from the line of Jonathan Chang from Leerink Partners. Your line is open. Speaker 600:36:45Hi, guys. Thanks for taking my questions. First question, can you speak to the enrollment experience of the Phase 3 SPD triplet study in multiple myeloma? And then second question, can you talk about how you're thinking about your cash position and runway and the converts due to mature in October 2025? Thank you. Speaker 200:37:06Yes. Thanks, Jonathan. For the first part of that, I'll turn to Reshma and then I'll let Mike touch on the second part of that. Speaker 300:37:14Yes. Thanks, Jonathan, for the question. So, the enrollment is going well with that SPD trial. It's an all oral, as Silhania mentioned. STD really represents the only all oral therapy. Speaker 300:37:26Obviously, it has some unique data pre and post T cell therapies, which in this evolving environment is going to be a key attribute for this combination. There's a lot of interest in this study, both in the U. S. As well as the EU. So we're driving towards enrollment and look forward to announcing completion of the enrollment later this year. Speaker 200:37:51Thanks. And on the second question, yes, we finished 2023 with $192,000,000 in cash. We burned approximately $88,000,000 in 2023, which gives us a cash runway with our what we're planning for exovio net revenue here in the U. S. As well as partnership revenues offset by spend over the next couple of years into late 2025. Speaker 200:38:14And as far as the convert goes, the convert is due in October 2025. So it certainly gives us some time. It's very closely held with the top 5 holders owning greater than 85 percent of the bonds. So we'll certainly be opportunistic in evaluating our options around the convert. Speaker 600:38:33Got it. Thanks for taking my questions. Speaker 200:38:36Thanks, Jonathan. Operator00:38:39And your next question comes from the line of Colleen Kosey from Baird. Your line is open. Speaker 700:38:46Great. Good morning. Thanks for taking our questions. Any comments you can offer on 1Q so far? I think you had mentioned last year that the 3rd party reimbursement foundations wouldn't be as impactful this year with IRA coming online. Speaker 700:38:59So can you just anything notable with the IRA rollout so far this year and any seasonality you're seeing yet in 1Q? Speaker 200:39:07Yes. Thanks, Colleen. I mean, I'll just talk about that at a high level. We just don't provide comments kind of inter quarter. So we'll update on Q1. Speaker 200:39:15But as we're progressing in Q1 here, we feel very good about being able to deliver our full year guidance. Speaker 700:39:23Great. And then with some exciting label expansion opportunities ahead, can you just make some comments, remind us on your IP position for selinexor? When does the composition matter expire and how long do you think you could be protected beyond that? Speaker 200:39:37Yes. Thanks, Colleen. As I think we've had some really positive evolution with regards to our IP position. And obviously, we work very hard to make sure we protect our valuable inventions here in the U. S. Speaker 200:39:50And globally. Last year in Q3, we were able to achieve kind of almost 1 year, 342 days of extension to our composition of matter patent. So that takes us to July of 2,033. And then in Q4 of last year, actually we were able to really work with patent office and enable to enhance our patents with regard to the polymorphic form of selinexor and the newly issued patents expire in August of 2,035. And we really believe that these polymorphic form used our API differentiated from other forms and really offers clear So for us a long runway in front of us with regards to patent protection. Speaker 700:40:36Great. That's helpful. Thanks for taking our questions. Speaker 200:40:39Thanks, Collyn. Operator00:40:43And your next question comes from the line of Brian Abrahams from RBC Capital Markets. Your line is open. Speaker 600:40:51Hi, this is Joe on for Brian. Thanks for taking our question. Question on the new monotherapy study in MF. I believe you're allowing add on therapies in the study. Can you talk about how many patients are expected to go on add on therapies over the course of the study? Speaker 600:41:08And also any synergistic benefits you may expect to see with pecretinib and momelitinib? Thank you. Speaker 200:41:16Yes. Thanks, Joe. I think when I'm sorry. Go ahead, Reshma. Speaker 300:41:21I jumped the gun. I apologize. It's a great question, Joe. So the monotherapy study, as you mentioned correctly, does allow the option the option to add on different therapies as early as week 12. Now with that said, if the patient is deriving benefit, both from an SVR and TSS perspective, we really want them to continue on selinexor monotherapy. Speaker 300:41:45And as I mentioned earlier, given all of the pre clinical and clinical data, we really do feel confident that selinexor monotherapy is going to drive that benefit across those two endpoints, which really suggests that a very small proportion if that is likely going to need an add on therapy in the form of momelatinib, picritinib or ruxolitinib. So, we'll wait to see as the study continues to roll out and as we see additional patients, we see patients being enrolled on the study. But again, I think it is going to be a small proportion of patients. Speaker 700:42:26Thanks so much. Speaker 200:42:28Thanks, Joe. Operator00:42:31And your next question comes from the line of Steve Birche from H. C. Wainwright. Your line is open. Speaker 800:42:39Hey, this is Steve on for Ed. So you were saying there was a shift, more of a shift into earlier lines of therapy in the increased duration of patient on drug. Can you put any numbers to that? And is there a difference between the 2nd line to 4th line and penorefractory patients? Speaker 200:42:59Yes. Thanks, Steve. I mean, I'll just add a high level, as you talked to that, looking at the numbers in detail is very difficult and it's more directional. And I'll turn to Sonja to talk about that impact as we're looking at the ongoing shift into the earlier lines, which again is right in line with our strategy and then where we're going to continue to focus. Sonja? Speaker 300:43:18Yes. So we continue to see an upward trend in our duration of therapy and that is really primarily driven by the early aligned patients who do tend to stay on therapy much longer than the later line patients. We are also seeing the duration increase because our physicians are getting more comfortable in managing these patients with the right supportive care at the lower dose and so on. So again, we won't disclose the specifics of the duration, but we see an upward trend and we expect to continue to see a positive shift in our duration as we move forward. Speaker 800:43:59Okay. Thanks for taking our questions. Speaker 200:44:03Thanks, Steve. Operator00:44:06Thank you. Our Q and A session has now ended. I would like to turn it back to Richard Paulson, President and Chief Executive Officer of CaioForm for closing comments. Speaker 200:44:16Thank you, Udi. And once again, thank you everyone for joining us today. I think as I mentioned before, we're very excited about our innovation and growth strategy. Our Phase 3 clinical trials are moving forward rapidly and we believe the largest opportunities for selinexor are yet to come as we focus on delivering this next phase of growth. And as we mentioned, everybody inside Karyopharm is focused on striving each day for patients' high unmet needs and working to generate value for our patients and shareholders. Speaker 200:44:43So once again, thank you for joining us today. Operator00:44:47Thank you. And ladies and gentlemen, this concludes today's conference call. Thank you for participating. You may now disconnect.Read morePowered by Conference Call Audio Live Call not available Earnings Conference CallKaryopharm Therapeutics Q4 202300:00 / 00:00Speed:1x1.25x1.5x2x Earnings DocumentsSlide DeckPress Release(8-K)Annual report(10-K) Karyopharm Therapeutics Earnings HeadlinesKaryopharm Therapeutics Inc. Common Stock (KPTI)April 23, 2025 | nasdaq.comKaryopharm Therapeutics Inc. Common Stock (KPTI)April 23, 2025 | nasdaq.comURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “gold analysts” have it all wrong… They tell you to invest in gold ETFs - because the popular mining ETFs will someday catch fire and close the price gap with spot gold. April 27, 2025 | Golden Portfolio (Ad)Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 1, 2025 | prnewswire.comKaryopharm price target lowered to split-adjusted $15 from $75 at Piper SandlerMarch 20, 2025 | markets.businessinsider.comKaryopharm Therapeutics (KPTI) Receives a Buy from Piper SandlerMarch 20, 2025 | markets.businessinsider.comSee More Karyopharm Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Karyopharm Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Karyopharm Therapeutics and other key companies, straight to your email. Email Address About Karyopharm TherapeuticsKaryopharm Therapeutics (NASDAQ:KPTI), a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.View Karyopharm Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Markets Think Robinhood Earnings Could Send the Stock UpIs the Floor in for Lam Research After Bullish Earnings?Texas Instruments: Earnings Beat, Upbeat Guidance Fuel RecoveryMarket Anticipation Builds: Joby Stock Climbs Ahead of EarningsIs Intuitive Surgical a Buy After Volatile Reaction to Earnings?Seismic Shift at Intel: Massive Layoffs Precede Crucial EarningsRocket Lab Lands New Contract, Builds Momentum Ahead of Earnings Upcoming Earnings Cadence Design Systems (4/28/2025)Welltower (4/28/2025)Waste Management (4/28/2025)AstraZeneca (4/29/2025)Mondelez International (4/29/2025)PayPal (4/29/2025)Starbucks (4/29/2025)DoorDash (4/29/2025)Honeywell International (4/29/2025)Regeneron Pharmaceuticals (4/29/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
There are 9 speakers on the call. Operator00:00:00Good morning. My name is Ludi, and I will be your conference operator today. At this time, I would like to welcome everyone to the Curuform Therapeutics 4th Quarter and Full Year 2023 Financial Results Conference Call. There will be a question and answer session to follow. Please be advised that this call is being recorded at the company's request. Operator00:00:21I would now like to turn the call over to Ellen Webb, Senior Vice President of Investor Relations. Please go ahead. Speaker 100:00:28Thank you, Luthie, and thank you all for joining us on today's conference call to discuss our financial results and recent company progress. We issued a press release this morning detailing our financial results for the Q4 and full year 2023. This release along with a slide presentation that we will reference during our call today are available on our website. For today's call, as seen on Slide 2, I'm joined by Richard, Reshma, Soania and Mike, who will provide an update on our results for the Q4 and full year 2023 and recent clinical developments. Before we begin our formal comments, I'll remind you that various remarks we'll make today constitute forward looking statements as follows for purposes of the Safe Harbor provisions under the Private Securities Litigation Reform Act of 1995 as outlined on Slide 3. Speaker 100:01:24Actual results may differ materially from those indicated by these FLX as a result of various important factors, including those discussed in the Risk Factors section of our most recent Form 10Q or 10 ks, which are on file with the SEC and in other filings that we may make with the SEC in the future. Any FLS represents our views as of today only. While we may elect to update these FLS at some point in the future, we specifically disclaim any obligation to do so even if our views change. Therefore, you should now rely on these FLS as Speaker 200:02:12Good morning. Thank you, Alhan, and thank you for joining us today for Karyopharm's Q4 and full year 2023 earnings call. My name is Richard Paulson, President and Chief Executive Officer of Karyopharm. As you can see on Slide 5, over the past few years, we have been intensely focused on positioning ourselves for our next stage of growth with 3 late stage trials supported by a growing body of unprecedented data in both solid and hematological malignancies that are expected to read out next year. The data we are seeing in myelofibrosis and endometrial cancer are highly encouraging and we believe the largest opportunities for selinexor are yet to come. Speaker 200:02:59These trials will potentially enhance and create new standards of care for patients and provide significant value creation opportunities in the near term. It is our top priority to advance this late stage pipeline, address patients' unmet needs and if approved, rapidly expand selinexor's use in new indications. We are doing this by concentrating our investments into these pivotal programs and leveraging our existing multiple myeloma franchise anchored on our commercial drug, EXPOVIO, which is approved in over 40 countries, generating brand profitability and growing experience with physicians. Through ongoing disciplined expense management, we have In 2023, we delivered total revenues of $146,000,000 meeting our guidance for full year and in 2024 we expect to generate $140,000,000 to $160,000,000 total revenues. This range reflects the highly competitive nature of the multiple myeloma market with important new entrants in the second half of twenty twenty three and more anticipated this year, which we are mindful of especially when setting expectations for our financial performance this year. Speaker 200:04:25This is balanced by the resilience we have demonstrated and our focus on both near term and long term growth. Importantly, our existing commercial infrastructure is profitable today and provides us with the capability to support the rapid and smooth commercial launch of selinexor in new indications. We are committed to delivering on the opportunities ahead of us and believe selinexor could generate approximately $2,000,000,000 of peak annual revenues in the U. S. Alone. Speaker 200:04:58And turning now to Slide 6, let's review some key accomplishments from our core programs in 2023, which strengthen our confidence in our ongoing Phase 3 trials. In myofibrosis, we are very encouraged by the comprehensive profile, including tolerability, spleen volume reduction, symptom improvement as measured by TSS-fifty and the long term durability that we saw in our Phase 1 data of selinexor plus ruxolitinib in JAK naive patients presented at ASH. In endometrial cancer, we are excited by the substantial improvement in median progression free survival for patients who are TP53 wild type as reported at the ASCO plenary series. This highlights the opportunity we may have to deliver unprecedented outcomes for a large and unique population of patients. In multiple myeloma, despite increased competition in the academic setting, we continued to grow EXPOVIO in the community setting and shifted its use to earlier lines of treatment. Speaker 200:06:06We look forward to the results from our Phase 3 trial evaluating selinexor at the well dose of 40 milligrams in combination with the well established backbone therapy of pomalidomide and dexamethasone post anti CD38 antibodies. Turning now to Slide 7, as we work to create new standards of care, we expect each of our ongoing Phase 3 clinical trials will read out top line results in 2025. Any one of these programs if approved represents an incredibly meaningful growth opportunity for our company with endometrial cancer and myelofibrosis representing the largest opportunities. Moving to Slide 8, I would now like to turn the call over to Reshma to expand further on our clinical pipeline progress. Reshma? Speaker 300:06:58Thank you, Richard, and good morning, everyone. As Richard mentioned on Slide 9, we have a very promising late stage pipeline with selinexor in 3 Phase 3 studies, all of which incorporate selinexor doses at 40 or 60 milligrams once weekly. Let's now turn our attention to myelofibrosis on Slide 11. Ruxolitinib remains the standard of care for the majority of JAK naive patients. However, there is an opportunity to improve benefit given that the efficacy with ruxolitinib is limited, with only about 35% of patients achieving an SVR35 and less than half of all patients achieving meaningful symptom improvement. Speaker 300:07:41Xpl1 inhibition is a fundamental mechanism in myelofibrosis, given that it targets both JAK and non JAK pathways, underscoring selinexor's additive is not potentially synergistic activity when dosed in combination. We are evaluating the potential for selinexor in combination with ruxolitinib to provide benefit across all of the hallmarks of the disease, including spleen reduction, symptom improvement, disease modification and stabilization, if not improvement of the cytopenias. As you can see on Slide 12, we presented updated data last year from our trial evaluating selinexor 60 milligrams with ruxolitinib in JAK inhibitor naive patients, which showed an SVR35 of 79% at week 24 in the intent to treat population. Importantly, amongst the evaluable patients, 100% achieved in SVR35 at any time. On Slide 13, both TSS 50 and absolute TSS showed very meaningful improvements at week 24. Speaker 300:08:4858% of the intent to treat and 78% of the efficacy evaluable achieved the TSS 50 response. For absolute TSS, an average 18.5 point improvement was observed in the efficacy evaluable population at the same time point. Compare these to historical ruxolitinib data where TSS 50 was observed in 42% to 46% of ruxolitinib treated patients and the average TSS improvement was 11 to 14 points. Moreover, on Slide 14, we see that all symptom domains are substantially improved with the selinexor combination with all domains achieving an approximately 50% or greater improvement compared to baseline. The absolute TSS, TSS-fifty and individual domain improvements are corroborated by cytokine data, which show that the pro inflammatory cytokines, which lead to myelofibrosis symptom development show rapid, deep and sustained reductions relative to baseline. Speaker 300:09:54Taken together, data demonstrate that the novel combination of selinexor plus ruxolitinib has the potential to maximize symptom improvement relative to ruxolitinib alone in the ongoing Phase 3 study. Shown on Slide 15, we find the durability data from the selinexor ruxolitinib combination very important for patients. As of the most recent data cut off, none of the week 24 SVR35 responders dosed at selinexor 60 milligrams had observed radiographic progressions and none of the week 24 TSS 50 responders had observed symptom progressions. While I acknowledge the apparent limitations in cross trial comparisons, contrast these data to ruxolitinib alone in which only approximately 70% of responses were ongoing at 78 weeks. As we move to Slide 16, when we look at SVR35 and TSS 50 together, we see that 50% of patients experienced both of these responses at week 24 and 75% experienced both SBR35 and TSS50 response at any time. Speaker 300:11:06On Slide 17, we see that in addition to the cytokine data, we also observed signs of disease modification with the stabilization in the hemoglobin levels of patients on Selinexor 60 milligrams in combination with ruxolitinib. This trend is unique with the Selinexor combination given that with ruxolitinib alone, hemoglobin levels drop after treatment initiation and tend to stay low. On Slide 18, prominent myelofibrosis leaders in the field are impressed with the profile this unique selinexor combination may provide JAK naive myelofibrosis patients. In fact, one of the most prominent opinion leaders and the principal investigator of the selinexor plus ruxolitinib Phase 3 study, Doctor. John Mascarenas noted that the combination is tolerable and that the spleen and symptom data observed to date from the Phase 1 study may significantly improve these outcomes in first line myelofibrosis. Speaker 300:12:05As the body of data grow and positively evolve, we maintain a high level of confidence in the ongoing Phase 3 study shown on Slide 19, which is evaluating the combination of selinexor 60 milligrams with ruxolitinib versus ruxolitinib alone in 306 JAK naive myelofibrosis patients. We are on track to report top line results in the second half of twenty twenty five. Turning now to endometrial cancer. As seen on Slide 21, there is a paradigm shift underway for treatment of women with advanced and recurrent endometrial cancer, the most common form of gynecologic cancer in the United States with increasing use of molecular classification. TP53 wild type represents a potentially unique, but fundamental biomarker in endometrial cancer. Speaker 300:12:58Today, for DMMR patients who represent approximately 20% of advanced recurrent endometrial cancer, the new FDA approved standard is dastarlimab in combination with chemotherapy, followed by dastarlimab maintenance. For PMMR, which represent the remaining 80% of patients, checkpoint inhibitors are not approved. As such, the primary treatment option is chemotherapy followed by watch and wait. Patients whose tumors are both PMMR and p53 wild type represent 40% to 55% of all advanced recurrent endometrial cancer patients. As you can see on Slide 22, long term follow-up from the TP53 wild type subgroup from the SIENDRA trial, which evaluated selinexor as a maintenance therapy and thus after completion of approximately 6 months of chemotherapy shows a median PFS for selinexor of 27.4 months and 5.2 months for placebo, corresponding to a hazard ratio of 0.41. Speaker 300:14:04These robust subgroup data demonstrate the potential to provide substantial benefit to a unique and sizable population defined by p53 status, which directly ties to selinexor's mechanism of action given that XPO1 inhibition retains p53 within the nucleus, thus enhancing cell kill. As shown on Slide 23, the benefit observed with selinexor in the PMMR subpopulation is even more impressive with a hazard ratio of 0.32 and a median PFS that was not reached as of our most recent data cut off. The preliminary overall survival is encouraging with the hazard ratio of 0.76 observed in all patients with TP53 wild type and hazard ratio of 0.57 in the subgroup of patients that are p53 wild type and PMMR. These efficacy data coupled with the generally manageable side effect profile suggests that oral selinexor is uniquely positioned as an optimal maintenance therapy where convenience, tolerability and meaningful efficacy are the hallmarks of the maintenance option. In fact, some of our patients are now reaching their 4th year on therapy. Speaker 300:15:21I'm excited to present additional follow-up data later this year. On Slide 24, you can see the design of our EC-forty two pivotal Phase 3 study, which will enroll approximately 220 women whose tumors are PP53 wild type. We look forward to presenting top line results in the first half of 2025. Turning now to multiple myeloma. As seen on Slide 26, we are expanding our multiple myeloma franchise with the ongoing Phase 3 trial that is evaluating selinexor at the low dose of 40 milligrams in combination with the well established backbone therapy of pomalidomide and dexamethasone post anti CD38 antibodies, which will drive earlier use. Speaker 300:16:07We are enrolling patients with relapsed refractory multiple myeloma who have received an anti CD38 antibody as their most recent therapy. As we are seeing positively evolving data with longer median CSS observed with selinexor 40 milligrams in combination with pomalidomide and dexamethasone, a beneficial outcome for these patients. Top line data are now expected in the first half of twenty twenty five. In summary, we have near term late stage opportunities supported by compelling data in our rapidly advancing pipeline that will potentially benefit multiple cancer patient populations of high unmet need building on our approved indications. With that, I will now hand it over to Solania to review our commercial highlights. Speaker 300:16:55Turning now to Slide 28 and our commercial highlights for the Q4 and full year 2023. In 2023, we achieved $112,000,000 Exovio net revenue meeting our guidance for the year. In the Q4 2023, exovio net revenues were 25,000,000 dollars During 2023, we achieved total demand growth in the community setting and shifted patient mix into earlier lines consistent with our strategy. We increased our breadth of use, growing our community prescribing sites of care by approximately 20% year over year. The community setting now represents 2 thirds of our business and is where the large majority of early aligned patients are treated. Speaker 300:17:46In Q4 2023, EXPOVIO new patient share was approaching 70% in the second to fourth lines, representing double digit growth year over year. This shift in mix of patients continues to drive higher refills as earlier line patients tend to stay on therapy longer. We faced some considerable headwinds in 2023, including increased competition from new entrants in the bispecific class in the later lines, which adversely impacted demand in the academic setting in the second half of twenty 23. Additionally, higher gross to net driven by increased 340B discounts and Medicaid rebates due to the Inflation Reduction Act and a significant increase in the free drug or patient assistance program utilization due to closures of multiple myeloma foundations adversely impacted our revenue. In 2023, PAP contributed to 10% of total demand versus 5% in 2022, resulting in roughly a $6,000,000 impact in 2023. Speaker 300:18:57As we turn to 2024, we are working to grow our multiple myeloma business versus last year and are guiding to a U. S. Exovio net product revenue range of $100,000,000 to 120,000,000 dollars We believe our guidance range reflects a balance of conviction in our near term growth strategy for XBOVIO, while also recognizing the increasingly competitive nature of the myeloma landscape. For Xpovio, we remain focused on growth in 3 key areas. 1st, the community setting. Speaker 300:19:34This is where majority of physicians tend to treat early aligned patients and are looking for agents that are effective, manageable and convenient. We believe that as DARZALEX use expands in the frontline, particularly in the community setting, it opens up new opportunities for XPOVIO in the 2nd or 4th lines. This is strengthened by our new data and elevation of selinexor in the NCCN guidelines. 2nd, earlier lines of therapy. We will remain focused on further shifting the use of selinexor into earlier lines of therapy where we see the benefit of increasing duration of therapy. Speaker 300:20:163rd, T cell fitness. We plan to further build on the evidence around the effectiveness of exposure pre and post T cell redirecting therapies, enabling a flexible position for selinexor in the treatment paradigm as a novel mechanism of action. As we look to the future of our multiple myeloma franchise, we believe that as a profitable business, generating a 2:one ROI, it will continue to provide a steady inflow of cash to fuel our pipeline and continue to drive confidence and experience in our product at a lower dose as we prepare for future launches, including the potential approval of the all oral SPD regimen, which could unlock further growth. Our story in multiple myeloma has been one of resilience and steadfastness in a highly competitive and rapidly evolving environment, where the disease remains incurable and EXPOVIO continues to be an effective option for many patients. Finally, our commercial organization is well established and has developed deep relationships in the community, which represents a key overlapping customer base in both myelofibrosis and endometrial cancer to enable rapid launches in these areas. Speaker 300:21:42Now I would like to turn the call over to Mike to give an update on our financials. Speaker 200:21:48Good morning, everyone, and thank you, Suhania. Turning to our financials, since we issued a press release earlier today with the full financial results, I will just focus on the highlights, which begin on Slide 30. Total revenue for the Q4 of 2023 was $33,700,000 similar to total revenue in the Q4 of 2022. Total revenue for the full year 2023 was $146,000,000 compared to $157,100,000 for the full year 2022. Net product revenue from U. Speaker 200:22:18S. Commercial sales of XPOVIO for the Q4 of 2023 was $25,100,000 compared to $31,100,000 for the Q4 of 2022. Net product revenue from U. S. Commercial sales of XPOVIO for the full year 2022 was $112,000,000 compared to $120,400,000 for the full year of 2022. Speaker 200:22:40The gross to net discount for XPOVIO in the Q4 of 2023 was 23.5% and for the full year 2023 was 22%. We expect the gross to net discount to be in the 25% to 30% range for the full year 2024 and as seen in previous years, it is expected to be at the higher end of the range for Q1. R and D expenses for the Q4 of 2023 were $39,400,000 compared to $30,900,000 for the Q4 of 2022 and $138,800,000 for the full year of 2023 compared to $148,700,000 for the full year 2022. The decrease in R and D expenses was primarily attributable to the decrease in personnel costs as a result of the reduction in headcount in line with the prioritization of our late stage clinical pipeline and decrease in severance related expenses. These decreases were partially offset by an increase in clinical trial and related costs, primarily due to the advancement of our 3 pivotal Phase III studies, which is expected to slightly increase our R and D expenses in 2024. Speaker 200:23:52SG and A expenses for the Q4 of 2023 were $30,700,000 compared to $34,600,000 for the Q4 of 2022. SG and A expenses for the full year of 2023 were $131,900,000 compared to $145,400,000 for the full year 2022. The decrease in SG and A expenses in 2023 compared to 2022 were due to a decrease in stock based compensation because of severance related expenses incurred in 2022. In 2024, we expect our SG and A expenses to slightly decrease as we continue to seek the benefits of our cost optimization efforts. On a non GAAP basis, which excludes stock based compensation, our total R and D and SG and A expenses in 2023 were $249,300,000 in line with our guidance for the year. Speaker 200:24:44Cash, cash equivalents, restricted cash and investments as of December 31, 20 Based on our current operating plans, we are expecting total revenue of $140,000,000 to $160,000,000 for 20.24 consisting of U. S. Exfoliovio net product revenue and license, royalty and milestone revenue expected to be earned from our partners, primarily Menarini and Antigene. We expect U. S. Speaker 200:25:17Exfoliovo net product revenue of $100,000,000 to $120,000,000 R and D and SG and A expenses to be in the range of $260,000,000 to $280,000,000 for the full year of 2024, including expected stock based compensation expense of 20 $1,000,000 to $25,000,000 And finally, that our existing cash, cash equivalents and investments as well as the revenue we expect to generate from XPOVIO net product sales and other license revenues will be sufficient to fund our planned operations into late 2025. In summary, we continue to be very diligent in allocation of our resources and looking at our projected 2024 expenses, we see the results of our pipeline prioritization and headcount reductions over the past couple of years. We are rapidly advancing our 3 Phase III trials and driving our commercial performance while keeping overall expense growth minimal. I'll now flip to Slide 31 and turn the call over to Richard for some final thoughts. Richard? Speaker 200:26:15Thank you, Mike. As you can see on Slide 32, we are excited about our innovation and growth strategy with our Phase 3 clinical trials in multiple myeloma, endometrial cancer and myelofibrosis, each of which would be transformative for patients and our organization. As I mentioned at the start of the call, we believe the largest opportunities for selinexor are yet to come. With data expected from these 3 Phase 3 trials next year, it's going to be an incredibly exciting time for our organization. We are focused on delivering on our next phase of growth as our people continue to strive each day for patients with high unmet needs, working to generate value for patients and shareholders. Speaker 200:27:01Thank you again for joining us today. And I would now like to ask the operator to open the call up to the Q and A portion of today's call. Operator? Operator00:27:12Thank you. You. And your first question comes from the line of Peter Lawson from Barclays. Your line is open. Speaker 400:27:44Great. Thanks so much. Maybe a question for Mike or Sonia, just around there's any way to kind of quantify the community versus academic setting growth in 'twenty three and kind of what that you think that looks like exiting the year and into 2024? Speaker 200:28:05Yes. Thanks, Peter, for the question. I think when you look overall, I think as Sonja talked to during our prepared comments, you really need to differentiate the environment between the community setting and the academic setting. And I'll turn to Sohane to elaborate on that looking at 2023 into 2024. Speaker 300:28:23Thanks, Peter, for the question. In 2023, as we take a step back, despite the rapid evolution in the competitive landscape, we did achieve total demand growth year over year in 20 23 in the community setting. This is an area of hyper focus for us and a clear growth driver for us in 2024. Another key accomplishment in the community for us in 2023 is we really broadened our sites of care. So we now have a broad base of prescribers. Speaker 300:28:57We increased our prescriber base by about 20% year over year. That is an area where we want to drive depth in the community in 2024. Again, this is the largest contributor of our business. It's about 2 thirds of our business. Switching to the academic setting that contributes to about a third of our business, and this is where we see rapid evolution of the competitive landscape. Speaker 300:29:22So last year, we were really in the eye of the storm, especially in the second half of the year, where we saw downward demand pressure as a result of the uptake of the bispecific class. 2 of the 3 bispecifics launched in the second half of last year. Now as we move into 2024, we do see a couple of new dynamics come into play, potential approval of a 4th bispecific potential shifts of CAR Ts into earlier lines. However, in terms of defending our business in the academic setting, it's really around enabling a flexible position for selinexor as a novel mechanism that's easily combinable and supported by our T cell fitness data. So that allows us to really play in the potential pre and post T cell therapy space in the academic setting. Speaker 400:30:19Perfect. Thank you. And then just the impact of BCMA therapies, do you think that kind of continues through 2024? Have you seen kind of the major shift already kind of happened? Speaker 300:30:34Yes. So the bispecifics, as I touched on, really posed a significant competitive threat in the academic setting, particularly in the second half of last year. As I mentioned, 2 of the 3 launched in the second half. Now we haven't seen that uptake in the community. We think that's going to be minimal impact in the near term in the community. Speaker 300:30:59But in the academic setting, we definitely saw impact. Now in real world, we are seeing that these patients are on bispecifics for about 8 to 9 months. Many are progressing. So it's not a curable option. As we think about the role of selinexor relative to the bispecifics, we have published data on positive outcomes post BCMA failures. Speaker 300:31:24So that really allows us to position ourselves after a bispecific and in many cases pre bispecifics as well. Speaker 400:31:35Thank you so much. I'll jump back into the queue. Speaker 200:31:39Thanks, Peter. Operator00:31:40Thank you. And your next question comes from the line of Maury Raycroft from Jefferies. Your line is open. Speaker 500:31:50Hi, good morning and thanks for taking my questions. I was going to ask 1 or 2 on myelofibrosis. Wondering what your thoughts are on the recent acquisition of MorphoSys and what read throughs there would be to carry a farm based on how the regulatory process could play out, particularly on the TSS endpoint, which was their key secondary, but is your co primary endpoint? And could you potentially have further conversations with FDA prior to filing and or change the study design, if need be? Speaker 200:32:23Thanks, Maury. I'll take the first part of that and then I'll turn it over to Reshma to take the second part of that. I think when you look at the Novartis and MorphoSys acquisition, it really validates the high unmet need in the myelofibrosis space and really talks to the value of the opportunity of myelofibrosis. So I think that's a strong validation of the value and the unmet need in myelofibrosis. And I'll turn to Reshma to talk about what we're looking at in terms of the evolution and I think we're really in a strong opportunity to watch the evolution of the space as it moves forward. Speaker 300:33:00Yes, exactly. And thank you for the question, Maury. I think what we presented today really just outlines the strength that we have across the entire profile of selinexor ruxolitinib, specifically the optimal spleen volume reduction, the symptom improvement, right, not only from a TSS-fifty perspective, but also now absolute TSS-fifty. We further looked at individual domains seeing maximal effect across each of the individual domains too. And all of that is of course underscored by the cytokine data. Speaker 300:33:35So really a wealth and growing sort of data set around that symptom score that really suggests that we can maximize benefit across both of those endpoints. Let's not forget disease modification and then of course improvement and stabilization of the cytopenia. So again, really just emphasizing that we have the totality profile that is going to be optimal for this JAK naive patient population. We're very encouraged and we're very confident that when we look at symptoms in our Phase 3, it is going to show meaningful benefit compared to selinexor alone. As Richard mentioned, I think we've got the best opportunity, right? Speaker 300:34:18We have an ongoing Phase 3. It's currently enrolling. We do know that the environment is evolving, both from a physician perspective, but also from an FDA perspective. And we're going to capitalize on that. So if there's an opportunity to evolve the endpoints, we have an opportunity to then of course incorporate those into our study prior to the database lock. Speaker 500:34:46Okay. That's helpful. And maybe one other question. You plan to report the preliminary results from the monotherapy Phase 2 inject naive myelofibrosis with moderate thrombocytopenia in the second half of this year. Can you talk more about what the strategy is for that study? Speaker 500:35:04Is this for potential standalone monotherapy approval path or more for supplementing the combination filing in label? Speaker 300:35:12Yes. Great question. So one of the unique aspects of selinexor is that when we look at preclinical data, obviously, clinical data from a relapsed refractory myelofibrosis study, which is the essential study. And then of course the subgroup data from our Phase 1 selinexor plus ruxolitinib, it all points to very intriguing monotherapy activity. Again, this is unique. Speaker 300:35:36When you look at other mechanisms of action, whether it's a BET inhibitor or a BCL2 inhibitor, those agents by and large do not have that critical monotherapy activity. It's key that physicians ultimately have that flexibility in that dosing. We want to use this Phase 2 study to further investigate this monotherapy activity in this high Aetna patient population. We'll have an opportunity to read out some data later this year and really be able to identify whether that activity is meaningful again in that high net need patient population. We're really looking at this as a proof of concept study. Speaker 300:36:20Potentially, we can expand it, potentially get some NCCN, but right now, it's really to double down and better test this hypothesis that we have with selinexor again in this JAK naive population. Speaker 500:36:32Got it. Okay. Thanks for taking my questions. Speaker 200:36:35Thanks, Marty. Operator00:36:38And your next question comes from the line of Jonathan Chang from Leerink Partners. Your line is open. Speaker 600:36:45Hi, guys. Thanks for taking my questions. First question, can you speak to the enrollment experience of the Phase 3 SPD triplet study in multiple myeloma? And then second question, can you talk about how you're thinking about your cash position and runway and the converts due to mature in October 2025? Thank you. Speaker 200:37:06Yes. Thanks, Jonathan. For the first part of that, I'll turn to Reshma and then I'll let Mike touch on the second part of that. Speaker 300:37:14Yes. Thanks, Jonathan, for the question. So, the enrollment is going well with that SPD trial. It's an all oral, as Silhania mentioned. STD really represents the only all oral therapy. Speaker 300:37:26Obviously, it has some unique data pre and post T cell therapies, which in this evolving environment is going to be a key attribute for this combination. There's a lot of interest in this study, both in the U. S. As well as the EU. So we're driving towards enrollment and look forward to announcing completion of the enrollment later this year. Speaker 200:37:51Thanks. And on the second question, yes, we finished 2023 with $192,000,000 in cash. We burned approximately $88,000,000 in 2023, which gives us a cash runway with our what we're planning for exovio net revenue here in the U. S. As well as partnership revenues offset by spend over the next couple of years into late 2025. Speaker 200:38:14And as far as the convert goes, the convert is due in October 2025. So it certainly gives us some time. It's very closely held with the top 5 holders owning greater than 85 percent of the bonds. So we'll certainly be opportunistic in evaluating our options around the convert. Speaker 600:38:33Got it. Thanks for taking my questions. Speaker 200:38:36Thanks, Jonathan. Operator00:38:39And your next question comes from the line of Colleen Kosey from Baird. Your line is open. Speaker 700:38:46Great. Good morning. Thanks for taking our questions. Any comments you can offer on 1Q so far? I think you had mentioned last year that the 3rd party reimbursement foundations wouldn't be as impactful this year with IRA coming online. Speaker 700:38:59So can you just anything notable with the IRA rollout so far this year and any seasonality you're seeing yet in 1Q? Speaker 200:39:07Yes. Thanks, Colleen. I mean, I'll just talk about that at a high level. We just don't provide comments kind of inter quarter. So we'll update on Q1. Speaker 200:39:15But as we're progressing in Q1 here, we feel very good about being able to deliver our full year guidance. Speaker 700:39:23Great. And then with some exciting label expansion opportunities ahead, can you just make some comments, remind us on your IP position for selinexor? When does the composition matter expire and how long do you think you could be protected beyond that? Speaker 200:39:37Yes. Thanks, Colleen. As I think we've had some really positive evolution with regards to our IP position. And obviously, we work very hard to make sure we protect our valuable inventions here in the U. S. Speaker 200:39:50And globally. Last year in Q3, we were able to achieve kind of almost 1 year, 342 days of extension to our composition of matter patent. So that takes us to July of 2,033. And then in Q4 of last year, actually we were able to really work with patent office and enable to enhance our patents with regard to the polymorphic form of selinexor and the newly issued patents expire in August of 2,035. And we really believe that these polymorphic form used our API differentiated from other forms and really offers clear So for us a long runway in front of us with regards to patent protection. Speaker 700:40:36Great. That's helpful. Thanks for taking our questions. Speaker 200:40:39Thanks, Collyn. Operator00:40:43And your next question comes from the line of Brian Abrahams from RBC Capital Markets. Your line is open. Speaker 600:40:51Hi, this is Joe on for Brian. Thanks for taking our question. Question on the new monotherapy study in MF. I believe you're allowing add on therapies in the study. Can you talk about how many patients are expected to go on add on therapies over the course of the study? Speaker 600:41:08And also any synergistic benefits you may expect to see with pecretinib and momelitinib? Thank you. Speaker 200:41:16Yes. Thanks, Joe. I think when I'm sorry. Go ahead, Reshma. Speaker 300:41:21I jumped the gun. I apologize. It's a great question, Joe. So the monotherapy study, as you mentioned correctly, does allow the option the option to add on different therapies as early as week 12. Now with that said, if the patient is deriving benefit, both from an SVR and TSS perspective, we really want them to continue on selinexor monotherapy. Speaker 300:41:45And as I mentioned earlier, given all of the pre clinical and clinical data, we really do feel confident that selinexor monotherapy is going to drive that benefit across those two endpoints, which really suggests that a very small proportion if that is likely going to need an add on therapy in the form of momelatinib, picritinib or ruxolitinib. So, we'll wait to see as the study continues to roll out and as we see additional patients, we see patients being enrolled on the study. But again, I think it is going to be a small proportion of patients. Speaker 700:42:26Thanks so much. Speaker 200:42:28Thanks, Joe. Operator00:42:31And your next question comes from the line of Steve Birche from H. C. Wainwright. Your line is open. Speaker 800:42:39Hey, this is Steve on for Ed. So you were saying there was a shift, more of a shift into earlier lines of therapy in the increased duration of patient on drug. Can you put any numbers to that? And is there a difference between the 2nd line to 4th line and penorefractory patients? Speaker 200:42:59Yes. Thanks, Steve. I mean, I'll just add a high level, as you talked to that, looking at the numbers in detail is very difficult and it's more directional. And I'll turn to Sonja to talk about that impact as we're looking at the ongoing shift into the earlier lines, which again is right in line with our strategy and then where we're going to continue to focus. Sonja? Speaker 300:43:18Yes. So we continue to see an upward trend in our duration of therapy and that is really primarily driven by the early aligned patients who do tend to stay on therapy much longer than the later line patients. We are also seeing the duration increase because our physicians are getting more comfortable in managing these patients with the right supportive care at the lower dose and so on. So again, we won't disclose the specifics of the duration, but we see an upward trend and we expect to continue to see a positive shift in our duration as we move forward. Speaker 800:43:59Okay. Thanks for taking our questions. Speaker 200:44:03Thanks, Steve. Operator00:44:06Thank you. Our Q and A session has now ended. I would like to turn it back to Richard Paulson, President and Chief Executive Officer of CaioForm for closing comments. Speaker 200:44:16Thank you, Udi. And once again, thank you everyone for joining us today. I think as I mentioned before, we're very excited about our innovation and growth strategy. Our Phase 3 clinical trials are moving forward rapidly and we believe the largest opportunities for selinexor are yet to come as we focus on delivering this next phase of growth. And as we mentioned, everybody inside Karyopharm is focused on striving each day for patients' high unmet needs and working to generate value for our patients and shareholders. Speaker 200:44:43So once again, thank you for joining us today. Operator00:44:47Thank you. And ladies and gentlemen, this concludes today's conference call. Thank you for participating. You may now disconnect.Read morePowered by